Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

By Poyurovsky Michael   Fuchs Camil   Pashinian Artashez   Levi Aya   Faragian Sarit   Maayan Rachel   Gil-Ad Irit  

Psychopharmacology, Vol. 192, Iss. 3, 2007-06 ,pp. : 441-448

Springer Publishing Company

Access to resources Recommend Favorite

Effect of Cilostazol on Lipid, Uric Acid and Glucose Metabolism in Patients with Impaired Glucose Tolerance or Type 2 Diabetes Mellitus: A Double-Blind, Placebo-Controlled Study

By Toyota T.  

Clinical Drug Investigation, Vol. 21, Iss. 5, 2001-01 ,pp. : 325-335

Adis International

Access to resources Recommend Favorite

Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study

By Kereiakes Dean J.  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 4, 2010-08 ,pp. : 239-246

Adis International

Access to resources Recommend Favorite

Seroquel TM treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens

By Link C.G.G.   Arvanitis L.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 346-347

Elsevier

Access to resources Recommend Favorite

Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study

By Murphy K.R.  

Clinical Drug Investigation, Vol. 20, Iss. 5, 2000-11 ,pp. : 337-349

Adis International

Access to resources Recommend Favorite